Overview

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
0
Participant gender:
Male
Summary
This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Metro West Medical Center
Saint Anne's Hospital
Treatments:
Androgens
Flutamide
Goserelin
Criteria
Inclusion Criteria:

- Biopsy proven prostate cancer

- Negative bone scan

- Lymph nodes by CT or MRI

- Adequate blood work

- Performance Status - ECOG 0-1

- Life expectancy of at least 10 years

- >40 years of age

Exclusion Criteria:

- Prior history of malignancy

- Prior hormonal therapy or chemotherapy

- Prior pelvic radiation therapy

- Unable to tolerate lying still 5-10 minutes/day